Deutsche Bank initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $40 price target The company two “de-risked, commercially validated” mechanisms in olverembatinib and Lisaftoclax, the analyst tells investors in a research note. The firm believes Lisaftoclax is positioned for continued commercial traction in China, which provides immediate access to larger patient volumes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma management to meet with Piper Sandler
- Ascentage Pharma management to meet with BTIG
- Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend
- Ascentage Pharma initiated with a Buy at BTIG
- Ascentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax